DDIT3 and non-Hodgkin lymphoma: So, to investigate the reason behind the differential response following R-CHOP therapy, we have immunoprofiled PBMCs obtained from NHL patients’ blood having both pre-chemotherapy (n=10) and post-chemotherapy (n=51) after 15 days from completion of R-CHOP therapy along with age and sex matched healthy individuals (n=10) (Figure 1A).